<DOC>
	<DOC>NCT00799942</DOC>
	<brief_summary>The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.</brief_summary>
	<brief_title>Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Nystagmus, Pathologic</mesh_term>
	<mesh_term>Nystagmus, Congenital</mesh_term>
	<criteria>patients who has succesfully completed the leadin study MRZ 925790707/1 Occurence of any major treatmentemergent adverse event or condition during the previous protocol (MRZ 925790707/1)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Nystagmus, congenital idiopathic</keyword>
</DOC>